Optimi Health Launches Standardized 1mg and 2mg Microdose Psilocybin Products for Clinical Research
Summary
Optimi Health Corp. announced the production of new 1mg and 2mg standardized microdose psilocybin products, targeting clinical research organizations with consistent, validated doses.
Key Events
-
New Microdose Psilocybin Products
Optimi Health has completed production of 1mg and 2mg standardized microdose psilocybin finished drug products.
-
Targeting Clinical Research
These products are specifically designed for qualified clinical research organizations, providing consistent, validated doses of naturally derived psilocybin.
-
Expanded Product Range
This expands Optimi's psilocybin portfolio, which already includes a 5mg capsule formulation commercially prescribed in Australia.
-
In-House GMP Production
All products are cultivated, extracted, formulated, and packaged in-house at Optimi's GMP-compliant facility in British Columbia, Canada.
Analysis
Optimi Health has launched new standardized microdose psilocybin products (1mg and 2mg) specifically for clinical research. This is important because it addresses a critical need in psychedelic research for consistent, validated doses, which is often a challenge with naturally derived products. Expanding their product line for research organizations could open new revenue streams and solidify their position as a key supplier in the emerging psychedelic medicine market.
At the time of this filing, OPTH was trading at $4.35 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $27.1M. The 52-week trading range was $3.00 to $8.84. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.